Persistent low carriage of serogroup A two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Kristiansen, Paul A ^a   Ba, Absatou Ky ^b   Ouédraogo, Abdoul Salam ^c   Sanou, Idrissa ^c,d   Ouédraogo, Rasmata ^e   Sangaré, Lassana ^d   Diomandé, Fabien ^f,g   Kandolo, Denis ^f   Saga, Inger Marie ^a   Misegades, Lara ^g   Clark, Thomas A ^g   Préziosi, Marie Pierre ^h,i   Caugant, Dominique A ^a,j  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b Laboratoire National de Sante Publique   (Burkina Faso)

^c Centre Hospitalier Universitaire Souro Sanou   (Burkina Faso)

^d Centre Hospitalier Universitaire Yalgado   (Burkina Faso)

^e Centre Hospitalier Universitaire Pediatrique Charles de Gaulle   (Burkina Faso)

^f World Health Organization Ouagadougou   (Burkina Faso)

^g CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^h Meningitis Vaccine Project   (France)

ⁱ WORLD HEALTH ORGANIZATION   (Switzerland)

^j UNIVERSITY OF OSLO   (Norway)

more..

Author keywords

Burkina Faso; Carriage; Conjugate vaccine; Herd immunity; MenAfriVac; Meningitis; Meningitis belt; MLST; Neisseria meningitidis

Indexed keywords

CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; MENINGOCOCCUS VACCINE; PENICILLIN G; RIFAMPICIN; TETRACYCLINE; FRPB PROTEIN, BACTERIA; OUTER MEMBRANE PROTEIN; PORIN; PORIN PROTEIN, NEISSERIA;

ADOLESCENT; ADULT; AGE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BURKINA FASO; CEREBROSPINAL FLUID ANALYSIS; CHILD; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; IMMUNOSURVEILLANCE; MALE; MENINGOCOCCOSIS; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA LACTAMICA; NEISSERIA MENINGITIDIS; PRESCHOOL CHILD; PREVALENCE; SCHOOL CHILD; SEROTYPE; SEX DIFFERENCE; VACCINATION; ASYMPTOMATIC INFECTIONS; CROSS-SECTIONAL STUDY; GENETICS; HETEROZYGOTE; INFANT; ISOLATION AND PURIFICATION; MASS IMMUNIZATION; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL INFECTIONS; MICROBIOLOGY; MULTILOCUS SEQUENCE TYPING; OROPHARYNX; YOUNG ADULT;

ADOLESCENT; ADULT; ASYMPTOMATIC INFECTIONS; BACTERIAL OUTER MEMBRANE PROTEINS; BURKINA FASO; CARRIER STATE; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INFANT; MALE; MASS VACCINATION; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MULTILOCUS SEQUENCE TYPING; NEISSERIA MENINGITIDIS, SEROGROUP A; OROPHARYNX; PORINS; PREVALENCE; VACCINATION; YOUNG ADULT;

EID: 84924058513     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-014-0663-4     Document Type: Article

References (50)

1. Greenwood B: Manson Lecture. Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg 1999, 93:341-353.
2. Teyssou R, Muros-Le RE: Meningitis epidemics in Africa: a brief overview. Vaccine 2007, 25(Suppl. 1):A3-A7.
3. Lapeyssonnie L: La méningite cérébrospinale en Afrique [in French]. Bull World Health Organ 1963, 28(Suppl):3-114.
4. Harrison LH, Trotter CL, Ramsay ME: Global epidemiology of meningococcal disease. Vaccine 2009, 27(Suppl. 2):B51-B63.
5. Stephens DS: Conquering the meningococcus. FEMS Microbiol Rev 2007, 31:3-14.
6. Yazdankhah SP, Caugant DA: Neisseria meningitidis: an overview of the carriage state. J Med Microbiol 2004, 53:9-32.
7. Boisier P, Maïnassara HB, Sidikou F, Djibo S, Kairo KK, Chanteau S: Case-fatality ratio of bacterial meningitis in the African meningitis belt: We can do better. Vaccine 2007, 25(Suppl. 1):A24-A29.
8. Nicolas P, Norheim G, Garnotel E, Djibo S, Caugant DA: Molecular epidemiology of Neisseria meningitidis isolated in the African meningitis belt between 1988 and 2003 shows dominance of sequence type 5 (ST-5) and ST-11 complexes. J Clin Microbiol 2005, 43:5129-5135.
9. Koumaré B, Ouédraogo-Traoré R, Sanou I, Yada AA, Sow I, Lusamba PS, Traoré E, Dabal M, Santamaria M, Hacen MM, Kaboré AB, Caugant DA: The first large epidemic of meningococcal disease caused by serogroup W135, Burkina Faso, 2002. Vaccine 2007, 25(Suppl. 1):A37-A41.
10. WHO: Control of Epidemic Meningococcal Disease. 2nd edition. WHO practical guidelines; 1998. WHO/EMC/BAC/983. Available from: http://www.who.int/csr/resources/publications/meningitis/whoemcbac983.pdf.
11. Wuorimaa T, Kayhty H, Eskola J, Bloigu A, Leroy O, Surcel HM: Activation of cell-mediated immunity following immunization with pneumococcal conjugate or polysaccharide vaccine. Scand J Immunol 2001, 53:422-428.
12. Maiden MCJ, Stuart JM: Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002, 359:1829-1830.
13. Forleo-Neto E, De Oliveira CF, Maluf EMCP, Bataglin C, Araujo JMR, Kunz J, Pustai AK, Vieira VSD, Zanella RC, Brandileone MC, Mimica LM, Mimica IM: Decreased point prevalence of Haemophilus influenzae type b (Hib) oropharyngeal colonization by mass immunization of Brazilian children less than 5 years old with Hib polyribosylribitol phosphate polysaccharide-tetanus toxoid conjugate vaccine in combination with diphtheria-tetanus toxoids- pertussis vaccine. J Infect Dis 1999, 180:1153-1158.
14. Maiden MCJ, Ibarz-Pavon AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, Walker AM, Evans MR, Kroll JS, Neal KR, Ala'aladeen DA, Crook DW, Cann K, Harrison S, Cinningham R, Baxter D, Kaczmarski E, Maclennan J, Cameron JC, Stuart JM: Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008, 197:737-743.
15. Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E: Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. Br Med J 2003, 326:365-366.
16. Vestrheim DF, Hoiby EA, Aaberge IS, Caugant DA: Impact of a pneumococcal conjugate vaccination program on carriage among children in Norway. Clin Vaccine Immunol 2010, 17:325-334.
17. LaForce FM, Konde K, Viviani S, Préziosi MP: The Meningitis Vaccine Project. Vaccine 2007, 25(Suppl):A97-A100.
18. LaForce FM, Okwo-Bele J-M: Eliminating epidemic group A meningococcal meningitis in Africa through a new vaccine. Health Aff (Millwood) 2011, 30:1049-1057.
19. Frasch CE, Préziosi MP, LaForce FM: Development of a group A meningococcal conjugate vaccine, MenAfriVac. Hum Vaccin Immunother 2012, 8:715-724.
20. Sow SO, Okoko BJ, Diallo A, Viviani S, Borrow R, Carlone G, Tapia M, Akinsola AK, Arduin P, Findlow H, Elie C, Haidara FC, Adegbola RA, Diop D, Parulekar V, Chaumont J, Martellet L, Diallo F, Idoko OT, Tang Y, Plikaytis BD, Kulkarni PS, Marchetti E, LaForce FM, Preziosi MP: Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 2011, 364:2293-2304.
21. Djingarey MH, Barry R, Bonkoungou M, Tiendrebeogo S, Sebgo R, Kandolo D, Lingani C, Préziosi MP, Zuber PLF, Perea W, Hugonnet S, de RTN D, Tevi-Benissan C, Clark TA, Mayer LW, Novak R, Messonier NE, Berlier M, Toboe D, Nshimirimana D, Mihigo R, Aguado T, Diomandé F, Kristiansen PA, Caugant DA, LaForce FM: Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience. Vaccine 2012, 30(Suppl):B40-B45.
22. Novak RT, Kambou JL, Diomandé FV, Tarbangdo TF, Ouédraogo-Traoré R, Sangaré L, Lingani C, Martin SW, Hatcher C, Mayer LW, LaForce FM, Avokey F, Djingarey MH, Messonier NE, Tiendrébéogo S, Clark TA: Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Lancet Infect Dis 2012, 12:757-764.
23. Kristiansen PA, Diomandé F, Absatou KB, Sanou I, Ouédraogo AS, Ouédraogo R, Sangaré L, Kandolo D, Aké F, Saga IM, Clark TA, Misegades L, Martin SW, Thomas JD, Tiendrebeogo SR, Hassan-King M, Djingarey MH, Messonnier NE, Préziosi MP, Laforce FM, Caugant DA: Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis 2013, 56:354-363.
24. Kristiansen PA, Ba AK, Sanou I, Ouédraogo AS, Ouédraogo R, Sangaré L, Diomandé F, Kandolo D, Thomas JD, Clark TA, LaForce M, Caugant DA: Phenotypic and genotypic characterization of meningococcal carriage and disease isolates in Burkina Faso after mass vaccination with a serogroup a conjugate vaccine. BMC Infect Dis 2013, 13:363.
25. Daugla D, Gami J, Gamougam K, Naibei N, Mbainadji L, Narbé M, Toralta J, Kodbesse B, Ngadoua C, Coldiron M, Fermon F, Page AL, Djingarey MH, Hugonnet S, Harrison OB, Rebbetts LS, Tekletsion Y, Watkins ER, Hill D, Caugant DA, Chandramohan D, Hassan-King M, Manigart O, Nascimento M, Woukeu A, Trotter C, Stuart JM, Maiden MC, Greenwood BM: Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community trial. Lancet 2013, 383:40-47.
26. Kristiansen PA, Diomandé F, Wei SC, Ouédraogo R, Sangaré L, Sanou I, Kandolo D, Kaboré P, Clark TA, Ouédraogo AS, Absatou KB, Ouédraogo CD, Hassan-King M, Thomas JD, Hatcher C, Djingarey M, Messonnier N, Préziosi MP, LaForce M, Caugant DA: Baseline meningococcal carriage in Burkina Faso before the introduction of a meningococcal serogroup A conjugate vaccine. Clin Vaccine Immunol 2011, 18:435-443.
27. Kristiansen PA, Ouédraogo AS, Sanou I, Absatou KB, Ouédraogo CD, Sangaré L, Ouédraogo R, Kandolo D, Diomandé F, Kaboré P, Hassan-King M, Thomas JD, Hatcher CP, Andreasson I, Clark TA, Préziosi MP, LaForce M, Caugant DA: Laboratory quality control in a multicentre meningococcal carriage study in Burkina Faso. Trans R Soc Trop Med Hyg 2012, 106:289-297.
28. STATA. Texas USA: Statacorp LP; [ www.stata.com ]
29. Ajello GW, Feeley JC, Hayes PS: Trans-isolate medium: a new medium for primary culturing and transport of Neisseria meningitidis , Streptococcus pneumoniae , and Haemophilus influenzae. J Clin Microbiol 1984, 20:1984.
30. Maiden MC, Bygraves JA, Feil E, Morelli G, Russell JE, Urwin R, Zhang Q, Zhou J, Zurth K, Caugant DA, Feavers IM, Achtman M, Spratt BG: Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A 1998, 95:3140-3145.
31. Russell JE, Jolley KA, Feavers IM, Maiden MCJ, Suker J: PorA variable regions of Neisseria meningitidis. Emerg Infect Dis 2004, 10:674-678.
32. Thompson EAL, Feavers IM, Maiden MCJ: Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component. Microbiology 2003, 149:1849-1858.
33. Taha M-K: Simultaneous approach for nonculture PCR-based identification and serogroup prediction of Neisseria meningitidis. J Clin Microbiol 2000, 38:855-857.
34. Caugant DA, Hoiby EA, Froholm LO, Brandtzaeg P: Polymerase chain reaction for case ascertainment of meningococcal meningitis: Application to the cerebrospinal fluids collected in the course of the Norwegian meningococcal serogroup B protection trial. Scand J Infect Dis 1996, 28:149-153.
35. Caugant DA, Kristiansen PA, Wang X, Mayer LW, Taha MK, Ouédraogo R, Kandolo D, Bougoudogo F, Sow S, Bonte L: Molecular characterization of invasive meningococcal isolates from countries in the African meningitis belt before introduction of a serogroup A conjugate vaccine. PLoS One 2012, 7:e46019.
36. WHO: Inter Country Support Team West Africa. WHO Meningitis Weekly Bulletin; [ http://www.meningvax.org/epidemic-updates.php ]
37. MacNeil JR, Medah I, Koussoubé D, Novak RT, Cohn AC, Diomandé FVK, Yelbeogo D, Kambou JL, Tarbangdo TF, Ouédraogo-Traoré R, Sangaré L, Hatcher C, Vuong J, Mayer LW, Djingarey MH, Clark TA, Messonnier NE: Neisseria meningitidis serogroup W, Burkina Faso, 2012. Emerg Infect Dis 2014, 20:394-399.
38. Kristiansen PA, Diomandé F, Ouédraogo R, Sanou I, Sangaré L, Ouédraogo AS, Ba AK, Kandolo D, Dolan Thomas J, Clark TA, Préziosi MP, LaForce FM, Caugant DA: Carriage of Neisseria lactamica in 1- to 29-year-old people in Burkina Faso: epidemiology and molecular characterization. J Clin Microbiol 2012, 50:4020-4027.
39. Medah I, Yélbeogo D, Kambou JL, Wannemuehler K, Goodson JL, Flannery B, Cohn A, Novak RT, Clark T, Messonnier NE, Meyer SA: Serogroup A meningococcal conjugate vaccine coverage after the first national mass immunization campaign - Burkina Faso, 2011. Morb Mortal Wkly Rep 2012, 61:1022-1024.
40. Beddek AJ, Li MS, Kroll JS, Jordan TW, Martin DR: Evidence for capsule switching between carried and disease-causing Neisseria meningitidis strains. Infect Immun 2009, 77:2989-2994.
41. Simoes MJ, Cunha M, Almeida F, Furtado C, Brum L: Molecular surveillance of Neisseria meningitidis capsular switching in Portugal, 2002-2006. Epidemiol Infect 2009, 137:161-165.
42. Wang Q, Shao Z, Wang X, Gao Y, Li M, Xu L, Xu J, Wang L: Genetic study of capsular switching between Neisseria meningitidis sequence type 7 serogroup A and C strains. Infect Immun 2010, 78:3883-3888.
43. Lancellotti M, Guiyoule A, Ruckly C, Hong E, Alonso JM, Taha MK: Conserved virulence of C to B capsule switched Neisseria meningitidis clinical isolates belonging to ET-37/ST-11 clonal complex. Microbes Infect 2006, 8:191-196.
44. Traore Y, Njanpop-Lafourcade BM, Adjogble KL, Lourd M, Yaro S, Nacro B, Drabo A, du Parent Chatelet I, Mueller JE, Taha MK, Borrow R, Nicolas P, Alonso JM, Gessner BG: The rise and fall of epidemic Neisseria meningitidis serogroup W135 meningitis in Burkina Faso, 2002-2005. Clin Infect Dis 2006, 43:817-822.
45. Nathan N, Rose AM, Legros D, Tiendrebeogo SR, Bachy C, Bjorlow E, Firmenich P, Guerin PJ, Caugant DA: Meningitis serogroup W135 outbreak, Burkina Faso, 2002. Emerg Infect Dis 2007, 13:920-923.
46. Fazio C, Neri A, Starnino S, Sofia T, Mastrantonio P, Stefanelli P: Characterization of invasive serogroup Y meningococci in Italy: prevalence of ST-23 Complex/Cluster A3. New Microbiol 2008, 31:467-472.
47. Hedberg ST, Toros B, Fredlund H, Olcen P, Molling P: Genetic characterisation of the emerging invasive Neisseria meningitidis serogroup Y in Sweden, 2000 to 2010. Euro Surveillance 2011, 16.
48. Ladhani SN, Lucidarme J, Newbold LS, Gray SJ, Carr AD, Findlow J, Ramsay ME, Kaczmarski EB, Borrow R: Invasive meningococcal capsular group Y disease, England and Wales, 2007-2009. Emerg Infect Dis 2012, 18:63-70.
49. Leimkugel J, Hodgson A, Forgor AA, Pfluger V, Dangy JP, Smith T, Achtman M, Gagneux S, Pluschke G: Clonal waves of Neisseria colonisation and disease in the African meningitis belt: eight-year longitudinal study in northern Ghana. PLoS Med 2007, 4:e101.
50. Tartof S, Cohn A, Tarbangdo F, Djingarey MH, Messonnier N, Clark TA, Kambou JL, Novak R, Diomandé FV, Medah I, Jackson ML: Identifying optimal vaccination strategies for serogroup A Neisseria meningitidis conjugate vaccine in the African meningitis belt. PLoS One 2013, 8:e63605.